专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US6124432A Process for purifying dermonecrotic toxin produced by Bordetella and toxoid 失效
标题翻译：用于纯化由博德特氏菌和类毒素产生的皮肤坏死毒素的方法
公开(公告)号：US6124432A
公开(公告)日：2000-09-26
申请号：US750166
申请日：1996-12-02
申请人： Toru Kawai , Toshihiro Ushijima , Kozo Takase , Hideo Fujikawa
发明人： Toru Kawai , Toshihiro Ushijima , Kozo Takase , Hideo Fujikawa
IPC分类号： A61K39/00 , A61P31/04 , C07K14/235 , C07K14/285 , C07K1/00 , A23J1/00 , C07K14/00 , C07K16/00
CPC分类号： C07K14/285 , C07K14/235 , A61K39/00
摘要： The present invention aims at providing a method for preparing dermonecrotic toxin, an improved toxoid of dermonecrotic toxin produced by Bordetelia and a toxoid mixture comprising said improved toxoid of dermonecrotic toxin produced by Bordetella and a toxoid of dermonecrotic toxin produced by Pasteurella. There is provided a method for partially purifying dermonecrotic toxin which comprises bringing a dermonecrotic toxin-containing solution into contact with a chromatographic gel sulfated by direct sulfation or a chromatographic gel to which a sulfated molecule is covalently bonded to thereby make the dermonecrotic toxin adsorbed on the gel, and eluting the adsorbed dermonecrotic toxin from the gel. There is also provided a toxoid obtained from dermonecrotic toxin produced by Bordetella, said dermonecrotic toxin being prepared by the above method for partially purifying dermonecrotic toxin, and a toxoid mixture prepared by mixing said toxoid and a toxoid of dermonecrotic toxin produced by toxigenic Pasteurella, said toxoid mixture being safe and effective for preventing the atrophic rhinitis in pigs.
摘要翻译： PCT No.PCT / JP95 / 01125 Sec。 371日期1996年12月2日第 102（e）日期1996年12月2日PCT提交1995年6月7日PCT公布。公开号WO95 / 34322 日期1995年12月21日本发明旨在提供一种制备皮肤坏死毒素的方法，由博德特利氏菌产生的改良的皮肤坏死毒素类毒素，以及由博德特氏菌产生的所述改良的皮肤坏死毒素类毒素和由巴斯德氏菌产生的皮肤坏死毒素类毒素的类毒素混合物。提供了部分纯化皮肤坏死毒素的方法，其包括将含有皮肤坏死毒素的溶液与通过直接硫酸化硫酸化的色谱凝胶接触，或者将硫酸化分子共价键合到色谱凝胶上，从而使皮肤坏死毒素吸附在凝胶，并从凝胶中洗脱吸附的皮肤坏死毒素。还提供了由博德特氏菌产生的皮肤坏死毒素获得的类毒素，所述皮肤坏死毒素通过上述部分纯化皮肤坏死毒素的方法制备，以及通过混合所述类毒素和由产毒巴斯德氏菌产生的皮肤坏死毒素类毒素制备的类毒素混合物，类毒素混合物对于预防猪萎缩性鼻炎是安全有效的。

2. 发明授权

US5814321A Oil adjuvant vaccine and method for preparing same 失效
标题翻译：油佐剂疫苗及其制备方法
公开(公告)号：US5814321A
公开(公告)日：1998-09-29
申请号：US758374
申请日：1996-11-29
申请人： Tokuji Miyahara , Kozo Takase , Koichi Saito , Yoko Kishimoto , Satoru Tokuyama
发明人： Tokuji Miyahara , Kozo Takase , Koichi Saito , Yoko Kishimoto , Satoru Tokuyama
IPC分类号： A61K39/39 , A61K45/00 , A61K9/107
CPC分类号： A61K39/39 , A61K2039/55566 , Y10S514/937 , Y10S514/938 , Y10S514/939 , Y10S514/943
摘要： A water-in-oil type oil adjuvant vaccine comprises 20 to 90% by weight of an oil phase A) which is in a liquid state at ordinary temperature; 0.5 to 30% by weight of an emulsifying agent comprising a non-ionic surfactant B) which is a partial ester derived from a polyhydric alcohol carrying at least three hydroxyl groups and a fatty acid and which is in a liquid state at 40.degree. C. and a polyoxyethylene (20 to 60 moles) hydroxy fatty acid triglyceride C); and 5 to 75% by weight of an aqueous phase D) containing a biologically acceptable and effective amount of antigens, and optionally E) 0.01 to 10% by weight of an amino acid or a salt thereof and 0.01 to 10% by weight of a non-reducing sugar or a sugar alcohol having at least 5 hydroxyl groups in the molecule. In addition, a water-in-oil-in-water type oil adjuvant vaccine comprises the foregoing water-in-oil type oil adjuvant vaccine as an internal phase and an outer aqueous phase F) comprising 0.2 to 20% by weight of an emulsifying agent which comprises a non-ionic surfactant and which has an overall HLB value of not less than 10. The oil adjuvant vaccines show a high ability to induce an antibody-production over a long period of time and are excellent in requirements for medicines such as stability and safety.
摘要翻译：油包油型油佐剂疫苗含有20〜90重量％的油相A），其在常温下为液态; 0.5至30重量％的包含非离子表面活性剂B）的乳化剂，其为衍生自至少三个羟基和脂肪酸的多元醇的偏酯，并且在40℃处于液态。和聚氧乙烯（20至60摩尔）羟基脂肪酸甘油三酯C）; 和5至75重量％的包含生物可接受和有效量的抗原的水相D），以及任选地E）0.01至10重量％的氨基酸或其盐和0.01至10重量％的非还原糖或分子中具有至少5个羟基的糖醇。此外，水包油包水型油佐剂疫苗包含上述油包水型油佐剂疫苗作为内相和外水相F），其包含0.2-20重量％的乳化剂药物，其包含非离子表面活性剂，其总体HLB值不小于10.油佐剂疫苗显示出在长时间内诱导抗体产生的高能力，并且对药物如稳定性和安全性。

3. 发明申请

US20080095796A1 Novel Infectious Burasal Disease Virus And Vaccine Containing Said Virus 审中-公开
标题翻译：新型传染性乳腺疾病病毒和含有病毒的疫苗
公开(公告)号：US20080095796A1
公开(公告)日：2008-04-24
申请号：US11547160
申请日：2004-09-07
申请人： Kenichi Yamazaki , Kozo Takase , Hideyuki Ohta , Masashi Sakaguchi
发明人： Kenichi Yamazaki , Kozo Takase , Hideyuki Ohta , Masashi Sakaguchi
IPC分类号： A61K39/00 , A61P31/14 , C07H21/00 , C07K14/00 , C12N7/00
CPC分类号： C07K14/005 , A61K2039/525 , C12N7/00 , C12N2720/10021 , C12N2720/10022
摘要： Novel infectious bursal disease (IBD) virus not protectable by the conventional IBD vaccines was isolated and a novel vaccine efficacious to said virus is provided. Novel IBD virus TY2 strain was isolated and its passage strains were obtained. TY2 strain has a distinct genetic type from those of the known IBD viral strains wherein a hypervariable region in VP2, a major host protective antigenic region of said virus, is cleaved with neither TaqI nor SspI but cleaved with MvaI into fragments of about 52 bp and about 422 bp. TY2 strain or the passage strain of said virus allows for production of an excellent vaccine to IBD.
摘要翻译：分离出不能被常规IBD疫苗保护的新型传染性法氏囊病（IBD）病毒，并提供对所述病毒有效的新型疫苗。分离出新型IBD病毒TY2菌株，获得其通过菌株。 TY2菌株具有与已知IBD病毒株不同的遗传型，其中所述病毒的主要宿主保护性抗原区VP2中的高变区不用TaqI或SspI切割，而是用MvaI切割成约52bp的片段，约422bp。 TY2菌株或所述病毒的通过菌株允许生产优良的IBD疫苗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式